News Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
0.1311 ^USD	+0.85%		+6.85%	-84.58%

Apr. 22	Sector Update: Health Care Stocks Advance Premarket Monday	MT
Apr. 22	Sector Update: Health Care	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 22	MT
Sector Update: Health Care	Apr. 22	MT
Vaxxinity Issues Shareholder Letter	Apr. 19	AQ
Vaxxinity Issues Shareholder Letter	Apr. 19	GL
Vaxxinity to Voluntarily Delist From Nasdaq; Shares Sink After Hours	Apr. 19	MT
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock	Apr. 19	GL
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting	Mar. 28	GL
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates	Mar. 27	GL
Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Vaxxinity : UB-312 Target Engagement - ADPD 2024	Mar. 12	PU
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024	Mar. 07	GL
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson?s Disease at AD/PD? 2024	Mar. 07	CI
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published	Feb. 15	GL
Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies	Feb. 15	CI
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024	Feb. 13	GL
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024	Feb. 13	AQ
Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	Feb. 13	CI
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	Jan. 30	GL
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	Jan. 30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Summary

Filters